Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 March 2021 | Story Dr Nitha Ramnath
Francois van Schalkwyk, Keenan Carelse, UFS Alumni, Bertus Jacobs, UFS, University of the Free State, alumni relations, IoT.nxt.

We are pleased to host Bertus Jacobs in our second episode of the Voices of the Free State podcast series. As Chief Technology Officer at IoT.nxt. (Internet of Things), Bertus’ mind is constantly searching for new techniques, and imparting these to his team of developers. Evident from his ‘always on’ approach, Jacobs has optimised his passion for turning ideas into mainstream realities. He co-founded a successful software company, CSS Software, which saw its humble beginnings grow from Bloemfontein-based to an international-footprinted company. CSS Software is regarded as having some of the most innovative products in its market segment and was acquired by a JSE-listed group.

François van Schalkwyk and Keenan Carelse, UFS alumni leading the university’s United Kingdom Alumni Chapter, have put their voices together to produce and direct the podcast series.  Intended to reconnect alumni with the university and their university experience, the podcasts will be featured on the first Monday of every month, ending in November 2021.  Our featured alumni share and reflect on their experiences at the UFS, how it has shaped their lives, and relate why their ongoing association with the UFS is still relevant and important. The podcasts are authentic conversations – they provide an opportunity for the university to understand and learn about the experiences of its alumni and to celebrate the diversity and touchpoints that unite them. 

Listen to the podcast: 

Our podcast guest

While studying towards his BScHons (Computer Science) at the University of the Free State, Bertus developed an SDK (Software Development Kit) with low-level integration into various graphics hardware.  

Bertus has researched many ways of contributing to the growing IT industry – from developing point-of-sale systems that still run today, qualifying as MCP and MCSE, engineering telematic and biometric solutions for clients (UFS was one of them). After being approached to consult in developing a solution for the government, his search for a certain hardware problem and his expertise in the IT realm resulted in his invention of a controller and the birth of the RAPTOR.  Reports that took eight weeks to compile previously, are now at the fingertips of those who need it – all through data harvesting and dashboarding that combines software and hardware. The world-changing RAPTOR delivers a complete IoT solution, which has been internationally validated as being at the forefront of the emerging IoT wave.  IoT.nxt was named Best Commercial and Best Overall Winner at the MTN Business M2M Awards in 2017.  

Stay tuned for episode three to be released on 5 April 2021. 

For further information regarding the podcast series, or to propose other alumni guests, please email us at alumnipodcast@ufs.ac.za 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept